IRIL Study (AMaRC 18-02)

A prospective Phase II study of Isatuximab Rescue for Inadequate response to Lenalidomide and Dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma.

The purpose of this study is to determine whether Isatuximab (a new drug), when combined with chemotherapy, improves response to treatment.

Participating sites can enroll patient into study at the outset, which will then ensure patient can access Isatuximab upon failure to achieve CR at cycle 9.

For more information please visit

Project Information

Institution:

Australasian Myeloma Research Consortium (AMaRC C/- Alfred Health)

Specialities:

Haematology

Oncology

Other (specify below)

End date:

​

Suitability:

​

Parts of research done:

Literature review, Research proposal, Ethics approval

Positions Available:

Researchers

Statistician

Data Collector

Current Funding:

Sanofi

​

Website

https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=376910

​

Contact

Hang Quach

Please fill out the form below to express your interest in this research project. It is free to contact a project owner and express interest in a project. We recommend writing a detailed message regarding why you are interested in the project (e.g. what skills you can bring to the team) or what information you are seeking (e.g. detail regarding the study duration). All information you provide will be shared with the primary researcher, including your contact details. Thank you for your interest in this project.